Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03336216 · ClinicalTrials.gov registry record · Phase 2

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

A Phase 2 study of Advanced Pancreatic Cancer, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 2
Development phase
205
Enrollment target
20
Study locations

NCT03336216 is a Phase 2 study of Advanced Pancreatic Cancer that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 205 participants, above the 47-participant average among 7 other Advanced Pancreatic Cancer trials with a reported enrollment target (336% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03336216, a Phase 2 study of Advanced Pancreatic Cancer, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 2
Development phase
205 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.

Conditions Studied

Advanced Pancreatic Cancer

Interventions

  • DRUG Fluorouracil
  • BIOLOGICAL Nivolumab
  • DRUG Nab-paclitaxel
  • DRUG Onivyde
  • BIOLOGICAL Cabiralizumab

Study Locations (20)

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Dana Farber Cancer Institute. - Boston
  • Local Institution - 0010 - Boston

Arizona

  • Mayo Clinic in Rochester, Minnesota - Phoenix
  • HonorHealth Research Institute - Scottsdale

Florida

  • Florida Cancer Specialists - South - Fort Myers
  • Florida Cancer Specialists - North - St. Petersburg

New York

  • Local Institution - 0012 - New York
  • Local Institution - 0005 - New York

Pennsylvania

  • Local Institution - 0006 - Philadelphia
  • Local Institution - 0009 - Pittsburgh

Texas

  • Local Institution - 0013 - Dallas
  • Local Institution - 0011 - Houston

California

  • Local Institution - 0007 - Los Angeles

Colorado

  • University Of Colorado - Aurora

Trial Details

FieldValue
Enrollment Target 205 participants
Start Date 2017-12-18
Est. Completion 2023-06-01
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03336216

The ClinicalTrials.gov registry entry for NCT03336216 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 47-participant average among 7 other Advanced Pancreatic Cancer trials with a reported enrollment target (336% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Pancreatic Cancer appearing as the primary indexed condition, and to 5 interventions - of which Fluorouracil is the first listed.

NCT03336216 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Massachusetts, Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT03336216 about?

NCT03336216 is a clinical study titled "A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer". The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.

What is the current status of trial NCT03336216?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 205 participants. The study started on 2017-12-18. Estimated completion is 2023-06-01.

What conditions does trial NCT03336216 study?

This clinical trial studies the following conditions: Advanced Pancreatic Cancer.

What interventions are being tested in trial NCT03336216?

The interventions under investigation include: Fluorouracil (DRUG), Nivolumab (BIOLOGICAL), Nab-paclitaxel (DRUG), Onivyde (DRUG), Cabiralizumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT03336216?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03336216 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Pancreatic Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.